NX
Nexalin Technology, Inc.
NXL · NASDAQ
$4.63 +5.23% (+$0.23)
1M -54.86%
Market Cap $3.74M
P/E Ratio -
Div. Yield -
ROE 278.25%
Bulios Fair Price
$4.35
6.0% downside
Current Price
$4.63
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NXL is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
38 /100
Fair P/B 2.46x
P/S 17.23x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 11.89%
Rev. growth 38.88%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 4,202.53%
Gross margin 148.42%
FCF margin 2,860.54%
Quality
1 /100
Poor ROA 299.21%
ROIC 600.62%
Asset turnover 0.07x
Debt
85 /100
Low Current ratio 1.25x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
1 /100
Unstable EPS volatility 108.77%
Beta 3.98x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NXL
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Mark White
Employees
8
Headquarters
Houston
Upcoming events
02 DEC
Earnings
Upcoming earnings report